Association between Health Insurance Type and Genetic Testing and/or Counseling for Breast and Ovarian Cancer
暂无分享,去创建一个
[1] Christine Y. Lu,et al. Genetic Testing and/or Counseling for Colorectal Cancer by Health Insurance Type , 2022, Journal of personalized medicine.
[2] S. Keyhani,et al. Access to Care, Cost of Care, and Satisfaction With Care Among Adults With Private and Public Health Insurance in the US , 2021, JAMA network open.
[3] B. Karlan,et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.
[4] D. Uyar,et al. Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers , 2021, The application of clinical genetics.
[5] David K Jones,et al. Changes In Health Insurance Coverage, Access To Care, And Income-Based Disparities Among US Adults, 2011-17. , 2020, Health affairs.
[6] E. Kohn,et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Caplan,et al. Genetic discrimination: emerging ethical challenges in the context of advancing technology , 2019, Journal of law and the biosciences.
[8] M. Cabana,et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. , 2019, JAMA.
[9] R. Green,et al. Genetic testing, insurance discrimination and medical research: what the United States can learn from peer countries , 2019, Nature Medicine.
[10] M. Dorschner,et al. Insurance coverage does not predict outcomes of genetic testing: The search for meaning in payer decisions for germline cancer tests , 2019, Journal of genetic counseling.
[11] S. Roth. What is genomic medicine? , 2019, Journal of the Medical Library Association : JMLA.
[12] J. Blum,et al. Barriers to the utilization of genetic testing and genetic counseling in patients with suspected hereditary breast and ovarian cancers , 2019, Proceedings.
[13] Jennifer M. Taber,et al. Genetic counseling, genetic testing, and risk perceptions for breast and colorectal cancer: Results from the 2015 National Health Interview Survey. , 2019, Preventive medicine.
[14] Megan C. Roberts,et al. Exploring Predictors of Genetic Counseling and Testing for Hereditary Breast and Ovarian Cancer: Findings from the 2015 U.S. National Health Interview Survey , 2019, Journal of personalized medicine.
[15] J. Newhouse,et al. Access to care among Medicaid and uninsured patients in community health centers after the Affordable Care Act , 2019, BMC Health Services Research.
[16] Angela Mariotto,et al. Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Anne Marie McCarthy. Persistent underutilization of BRCA1/2 testing suggest the need for new approaches to genetic testing delivery. , 2019, Journal of the National Cancer Institute.
[18] Rakesh R. Patel,et al. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Christine Y. Lu,et al. Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer , 2018, Journal of personalized medicine.
[20] Héctor E Alcalá,et al. Insurance Type and Access to Health Care Providers and Appointments Under the Affordable Care Act , 2018, Medical care.
[21] M. P. Douglas,et al. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[22] Alaa M Althubaiti,et al. Information bias in health research: definition, pitfalls, and adjustment methods , 2016, Journal of multidisciplinary healthcare.
[23] Julie O. Culver,et al. Increased yield of actionable mutations using multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohort. , 2016, Cancer genetics.
[24] Zicheng Xu,et al. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review , 2016, Clinical Cancer Research.
[25] Yuya Kobayashi,et al. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. , 2015, JAMA oncology.
[26] L. Garrison,et al. Economic incentives for evidence generation: promoting an efficient path to personalized medicine. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[27] M. D. Graf,et al. Genetic testing insurance coverage trends: a review of publicly available policies from the largest US payers. , 2013, Personalized medicine.
[28] S. Haga,et al. Insurance Coverage Policies for Personalized Medicine , 2012, Journal of personalized medicine.
[29] M. Bush,et al. Multiple chronic conditions among adults aged 45 and over: trends over the past 10 years. , 2012, NCHS data brief.
[30] Joshua P Cohen,et al. Clinical and economic challenges facing pharmacogenomics , 2012, The Pharmacogenomics Journal.
[31] Peter J Neumann,et al. Personalized medicine: factors influencing reimbursement. , 2010, Health policy.
[32] Susan M. Domchek,et al. Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers , 2009, Journal of the National Cancer Institute.
[33] V. Shavers,et al. Racial and ethnic disparities in the receipt of cancer treatment. , 2002, Journal of the National Cancer Institute.
[34] D. Bentley,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.
[35] Steven E. Bayer,et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.
[36] Sitao Wu,et al. Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing , 2019, JAMA oncology.
[37] Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. , 2017, Obstetrics and gynecology.
[38] S. Modesitt,et al. Hereditary breast and ovarian cancer syndrome , 2011, Definitions.
[39] S. Markovic,et al. Genetic testing in colorectal cancer , 2013 .